Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23430662 | 0.91 | CCR2 (0.48) | SIGMAR1EPHX1CCR2EPHX2ALDH1A1 | |
| SCHEMBL20746937 | 0.90 | SMN1; SMN2 (0.53) | SIGMAR1EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL22414706 | 0.89 | CCR2 (0.56) | SIGMAR1EPHX1CCR2EPHX2 | |
| SCHEMBL14391301 | 0.86 | CCR2 (0.53) | SIGMAR1EPHX1CCR2EPHX2ALDH1A1 | |
| SCHEMBL25144357 | 0.83 | SIGMAR1 (0.48) | SIGMAR1EPHX1CCR2EPHX2KDM4E | |
| SCHEMBL19696814 | 0.82 | EPHX1 (0.59) | SIGMAR1EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL10308298 | 0.82 | EPHX1 (0.59) | SIGMAR1EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL9825772 | 0.82 | SIGMAR1 (0.57) | SIGMAR1EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL10103544 | 0.82 | SIGMAR1 (0.57) | SIGMAR1EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL2759379 | 0.80 | EPHX1 (0.56) | SIGMAR1EPHX1EPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550073-B2 | Benzamide derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-6887921-B2 | Ink follower composition for writing instruments, and process for its production | THE PILOT INK CO., LTD. (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030200896-A1 | Ink follower composition for writing instruments, and process for its production | THE PILOT INK CO., LTD. (JP) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550073-B2 | Benzamide derivative | CYP3A5, ABCB1, CYP2D6 | SIGMAR1 211/4885EPHX1 1725/4885CCR2 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.